{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T16:52:49Z","timestamp":1781455969052,"version":"3.54.1"},"reference-count":58,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association Inc","doi-asserted-by":"publisher","award":["PRE1019986"],"award-info":[{"award-number":["PRE1019986"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007270","name":"University of Michigan","doi-asserted-by":"publisher","award":["CS014"],"award-info":[{"award-number":["CS014"]}],"id":[{"id":"10.13039\/100007270","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["GM140223"],"award-info":[{"award-number":["GM140223"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.jtha.2025.11.011","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T08:14:40Z","timestamp":1765440880000},"page":"1042-1055","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Novel histone deacetylase inhibitor, CS014, attenuates in vivo thrombosis while maintaining hemostasis"],"prefix":"10.1016","volume":"24","author":[{"given":"Livia","family":"Stanger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pooja","family":"Yalavarthi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reheman","family":"Adili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devin","family":"Gilmore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Hoang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avery","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Krenik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Gustafsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Fryklund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Fex","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Oakes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas Faijerson","family":"S\u00e4lj\u00f6","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f6rn","family":"Dahl\u00f6f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Beckman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5100-1933","authenticated-orcid":false,"given":"Michael","family":"Holinstat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2025.11.011_bib1","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1161\/CIR.0000000000001123","article-title":"Heart disease and stroke statistics-2023 update: a report from the American Heart Association","volume":"147","author":"Tsao","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2025.11.011_bib2","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1016\/j.jacc.2022.11.005","article-title":"The global burden of cardiovascular diseases and risk: a compass for future health","volume":"80","author":"Vaduganathan","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jtha.2025.11.011_bib3","doi-asserted-by":"crossref","first-page":"3317","DOI":"10.1016\/j.jtha.2023.09.013","article-title":"Antiplatelet strategies: past, present, and future","volume":"21","author":"Stanger","year":"2023","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.11.011_bib4","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/s41573-020-0061-0","article-title":"Therapeutic strategies for thrombosis: new targets and approaches","volume":"19","author":"Mackman","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jtha.2025.11.011_bib5","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1124\/pr.117.014530","article-title":"Platelet signaling and disease: targeted therapy for thrombosis and other related diseases","volume":"70","author":"Yeung","year":"2018","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.jtha.2025.11.011_bib6","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1016\/S0140-6736(22)00563-3","article-title":"Making anticoagulation safer","volume":"399","author":"Gailani","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2025.11.011_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.903029","article-title":"Factor XI inhibitors for prevention and treatment of venous thromboembolism: a review on the rationale and update on current evidence","volume":"9","author":"Nopp","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.jtha.2025.11.011_bib8","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1182\/blood.2021013097","article-title":"Platelet ACKR3\/CXCR7 favors antiplatelet lipids over an atherothrombotic lipidome and regulates thromboinflammation","volume":"139","author":"Cebo","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.11.011_bib9","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1182\/blood-2014-05-575878","article-title":"Platelet 12-LOX is essential for Fc\u03b3RIIa-mediated platelet activation","volume":"124","author":"Yeung","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.11.011_bib10","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1161\/01.CIR.103.15.1936","article-title":"Impaired coronary tissue plasminogen activator release is associated with coronary atherosclerosis and cigarette smoking: direct link between endothelial dysfunction and atherothrombosis","volume":"103","author":"Newby","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2025.11.011_bib11","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1111\/j.1399-6576.2008.01741.x","article-title":"Impaired myocardial t-PA release in patients with coronary artery disease","volume":"52","author":"Osterlund","year":"2008","journal-title":"Acta Anaesthesiol Scand"},{"key":"10.1016\/j.jtha.2025.11.011_bib12","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1055\/s-0040-1718923","article-title":"Fibrinolysis in acute and chronic cardiovascular disease","volume":"47","author":"Kietsiriroje","year":"2021","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.jtha.2025.11.011_bib13","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1093\/cvr\/cvr028","article-title":"Epigenetic control of tissue-type plasminogen activator synthesis in human endothelial cells","volume":"90","author":"Dunoyer-Geindre","year":"2011","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jtha.2025.11.011_bib14","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s11239-012-0831-6","article-title":"Histone deacetylase inhibitors stimulate tissue-type plasminogen activator production in vascular endothelial cells","volume":"35","author":"Larsson","year":"2013","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.jtha.2025.11.011_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0031573","article-title":"Role of histone acetylation in the stimulatory effect of valproic acid on vascular endothelial tissue-type plasminogen activator expression","volume":"7","author":"Larsson","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jtha.2025.11.011_bib16","doi-asserted-by":"crossref","first-page":"715","DOI":"10.3390\/molecules27030715","article-title":"HDAC inhibitors: innovative strategies for their design and applications","volume":"27","author":"Da\u015bko","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.jtha.2025.11.011_bib17","doi-asserted-by":"crossref","first-page":"926","DOI":"10.2174\/1570159X17666181227165722","article-title":"Valproic acid and epilepsy: from molecular mechanisms to clinical evidences","volume":"17","author":"Romoli","year":"2019","journal-title":"Curr Neuropharmacol"},{"key":"10.1016\/j.jtha.2025.11.011_bib18","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1124\/pr.111.005512","article-title":"Therapeutic potential of mood stabilizers lithium and valproic acid: beyond bipolar disorder","volume":"65","author":"Chiu","year":"2013","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.jtha.2025.11.011_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2019.05.005","article-title":"Increased risk of stroke and myocardial infarction in patients with epilepsy: a systematic review of population-based cohort studies","volume":"104","author":"Brigo","year":"2020","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.jtha.2025.11.011_bib20","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1161\/STROKEAHA.117.016674","article-title":"Sodium valproate, a histone deacetylase inhibitor, is associated with reduced stroke risk after previous ischemic stroke or transient ischemic attack","volume":"49","author":"Brookes","year":"2018","journal-title":"Stroke"},{"key":"10.1016\/j.jtha.2025.11.011_bib21","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1002\/pds.3651","article-title":"Is sodium valproate, an HDAC inhibitor, associated with reduced risk of stroke and myocardial infarction? A nested case-control study","volume":"23","author":"Dregan","year":"2014","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jtha.2025.11.011_bib22","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1002\/pds.2186","article-title":"Effects of epilepsy and selected antiepileptic drugs on risk of myocardial infarction, stroke, and death in patients with or without previous stroke: a nationwide cohort study","volume":"20","author":"Olesen","year":"2011","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jtha.2025.11.011_bib23","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/pds.2073","article-title":"Valproate attenuates the risk of myocardial infarction in patients with epilepsy: a nationwide cohort study","volume":"20","author":"Olesen","year":"2011","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jtha.2025.11.011_bib24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0107582","article-title":"Profibrinolytic effect of the epigenetic modifier valproic acid in man","volume":"9","author":"Saluveer","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jtha.2025.11.011_bib25","article-title":"Histone deacetylase inhibition enhances tissue plasminogen activator release capacity in atherosclerotic man","volume":"10","author":"Svennerholm","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jtha.2025.11.011_bib26","doi-asserted-by":"crossref","first-page":"695","DOI":"10.2165\/00023210-200216100-00004","article-title":"Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience","volume":"16","author":"Perucca","year":"2002","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jtha.2025.11.011_bib27","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.clinbiochem.2013.06.012","article-title":"Adverse drug reactions induced by valproic acid","volume":"46","author":"Nanau","year":"2013","journal-title":"Clin Biochem"},{"key":"10.1016\/j.jtha.2025.11.011_bib28","doi-asserted-by":"crossref","first-page":"343","DOI":"10.2174\/1381612825666190329145428","article-title":"Valproic acid and the liver injury in patients with epilepsy: an update","volume":"25","author":"Guo","year":"2019","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.jtha.2025.11.011_bib29","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1097\/FPC.0b013e32835ea0b2","article-title":"Valproic acid pathway: pharmacokinetics and pharmacodynamics","volume":"23","author":"Ghodke-Puranik","year":"2013","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.jtha.2025.11.011_bib30","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S0090-9556(25)07155-7","article-title":"Identification and characterization of the glutathione and N-acetylcysteine conjugates of (E)-2-propyl-2,4-pentadienoic acid, a toxic metabolite of valproic acid, in rats and humans","volume":"19","author":"Kassahun","year":"1991","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.jtha.2025.11.011_bib31","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/0009-2797(94)90014-0","article-title":"Metabolic activation of unsaturated derivatives of valproic acid. Identification of novel glutathione adducts formed through coenzyme A-dependent and -independent processes","volume":"90","author":"Kassahun","year":"1994","journal-title":"Chem Biol Interact"},{"key":"10.1016\/j.jtha.2025.11.011_bib32","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1074\/jbc.M110.148726","article-title":"Regulation of heme oxygenase-1 protein expression by miR-377 in combination with miR-217","volume":"286","author":"Beckman","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jtha.2025.11.011_bib33","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1161\/ATVBAHA.117.309868","article-title":"First selective 12-LOX inhibitor, ML355, impairs thrombus formation and vessel occlusion in vivo with minimal effects on hemostasis","volume":"37","author":"Adili","year":"2017","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jtha.2025.11.011_bib34","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1182\/blood.2023020622","article-title":"The oxylipin analog CS585 prevents platelet activation and thrombosis through activation of the prostacyclin receptor","volume":"142","author":"Stanger","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.11.011_bib35","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1111\/jth.15184","article-title":"DHA 12-LOX-derived oxylipins regulate platelet activation and thrombus formation through a PKA-dependent signaling pathway","volume":"19","author":"Yamaguchi","year":"2021","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.11.011_bib36","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1097\/MBC.0000000000000836","article-title":"Thromboelastography testing in mice following blood collection from facial vein and cardiac puncture","volume":"30","author":"Kaur","year":"2019","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.jtha.2025.11.011_bib37","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S0005-2728(00)00058-X","article-title":"Calculation of isotope effects from first principles","volume":"1458","author":"Scheiner","year":"2000","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.jtha.2025.11.011_bib38","doi-asserted-by":"crossref","first-page":"36734","DOI":"10.1074\/jbc.M101287200","article-title":"Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen","volume":"276","author":"Phiel","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jtha.2025.11.011_bib39","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s40360-019-0294-x","article-title":"Histone deacetylase inhibition by Entinostat for the prevention of electrical and structural remodeling in heart failure","volume":"20","author":"Freundt","year":"2019","journal-title":"BMC Pharmacol Toxicol"},{"key":"10.1016\/j.jtha.2025.11.011_bib40","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1111\/jth.13527","article-title":"Valproic acid selectively increases vascular endothelial tissue-type plasminogen activator production and reduces thrombus formation in the mouse","volume":"14","author":"Larsson","year":"2016","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.11.011_bib41","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/clpt.1990.144","article-title":"Effects of polytherapy with phenytoin, carbamazepine, and stiripentol on formation of 4-ene-valproate, a hepatotoxic metabolite of valproic acid","volume":"48","author":"Levy","year":"1990","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jtha.2025.11.011_bib42","first-page":"212","article-title":"Analysis of variability of concentrations of valproic acid (VPA) and its selected metabolites in the blood serum of patients treated with VPA and patients hospitalized because of VPA poisoning","volume":"64","author":"Wilimowska","year":"2014","journal-title":"Arch Med Sadowej Kryminol"},{"key":"10.1016\/j.jtha.2025.11.011_bib43","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1161\/ATVBAHA.116.308050","article-title":"12(S)-HETrE, a 12-lipoxygenase oxylipin of dihomo-\u03b3-linolenic acid, inhibits thrombosis via G\u03b1s signaling in platelets","volume":"36","author":"Yeung","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jtha.2025.11.011_bib44","doi-asserted-by":"crossref","first-page":"80","DOI":"10.4174\/astr.2023.104.2.80","article-title":"Postoperative major bleeding risk in patients using oral antiplatelets and\/or anticoagulants after laparoscopic gastric cancer surgery","volume":"104","author":"Im","year":"2023","journal-title":"Ann Surg Treat Res"},{"key":"10.1016\/j.jtha.2025.11.011_bib45","doi-asserted-by":"crossref","DOI":"10.1177\/23094990211042674","article-title":"Application of thromboelastography in comparing coagulation difference of rivaroxaban and enoxaparin for thromboprophylaxis after total hip arthroplasty","volume":"29","author":"Bai","year":"2021","journal-title":"J Orthop Surg (Hong Kong)"},{"key":"10.1016\/j.jtha.2025.11.011_bib46","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1527-3458.2003.tb00249.x","article-title":"Valproate: past, present, and future","volume":"9","author":"Johannessen","year":"2003","journal-title":"CNS Drug Rev"},{"key":"10.1016\/j.jtha.2025.11.011_bib47","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1038\/s41598-021-81794-4","article-title":"Valproic acid influences the expression of genes implicated with hyperglycaemia-induced complement and coagulation pathways","volume":"11","author":"Felisbino","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.jtha.2025.11.011_bib48","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0264351","article-title":"Assessment of need for hemostatic evaluation in patients taking valproic acid: A retrospective cross-sectional study","volume":"17","author":"Post","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.jtha.2025.11.011_bib49","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1021\/acsptsci.2c00004","article-title":"Comparison of cellular target engagement methods for the tubulin deacetylases Sirt2 and HDAC6: NanoBRET, CETSA, tubulin acetylation, and PROTACs","volume":"5","author":"Vogelmann","year":"2022","journal-title":"ACS Pharmacol Transl Sci"},{"key":"10.1016\/j.jtha.2025.11.011_bib50","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1038\/s41467-017-01690-2","article-title":"Critical role of the HDAC6-cortactin axis in human megakaryocyte maturation leading to a proplatelet-formation defect","volume":"8","author":"Messaoudi","year":"2017","journal-title":"Nature Commun"},{"key":"10.1016\/j.jtha.2025.11.011_bib51","doi-asserted-by":"crossref","first-page":"C1230","DOI":"10.1152\/ajpcell.00053.2013","article-title":"Histone deacetylase 6-mediated deacetylation of \u03b1-tubulin coordinates cytoskeletal and signaling events during platelet activation","volume":"305","author":"Aslan","year":"2013","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.jtha.2025.11.011_bib52","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1182\/blood-2012-05-428011","article-title":"HDAC6 controls the kinetics of platelet activation","volume":"120","author":"Sadoul","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.11.011_bib53","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1182\/bloodadvances.2022007409","article-title":"Histone deacetylase-6 modulates the effects of 4\u00b0C platelets on vascular endothelial permeability","volume":"7","author":"Miyazawa","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2025.11.011_bib54","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.jvs.2015.12.020","article-title":"Dual antiplatelet therapy reduces stroke but increases bleeding at the time of carotid endarterectomy","volume":"63","author":"Jones","year":"2016","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.jtha.2025.11.011_bib55","doi-asserted-by":"crossref","first-page":"937","DOI":"10.5603\/KP.a2018.0112","article-title":"Dual and triple antithrombotic therapies: current patterns of practice and controversies","volume":"76","author":"Crowther","year":"2018","journal-title":"Kardiol Pol"},{"key":"10.1016\/j.jtha.2025.11.011_bib56","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ijcard.2016.01.148","article-title":"Thrombelastography detects dabigatran at therapeutic concentrations in vitro to the same extent as gold-standard tests","volume":"208","author":"Solbeck","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jtha.2025.11.011_bib57","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/j.1528-1157.1992.tb02355.x","article-title":"Effect of valproate dose on formation of hepatotoxic metabolites","volume":"33","author":"Anderson","year":"1992","journal-title":"Epilepsia"},{"key":"10.1016\/j.jtha.2025.11.011_bib58","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0009-9120(01)00217-X","article-title":"CYP2E1-mediated modulation of valproic acid-induced hepatocytotoxicity","volume":"34","author":"Neuman","year":"2001","journal-title":"Clin Biochem"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783625008864?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783625008864?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T16:03:50Z","timestamp":1781453030000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783625008864"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":58,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S1538783625008864"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2025.11.011","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel histone deacetylase inhibitor, CS014, attenuates in vivo thrombosis while maintaining hemostasis","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2025.11.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}]}}